Stay updated with breaking news from Dan Forche. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Prelude Corporation (PreludeDx™), a leader in molecular diagnostics and precision medicine for early stage breast cancer, presented data at the...
PreludeDx PREDICT Study Demonstrates High Clinical Utility of DCISionRT for DCIS Breast Cancer Patients 42% change in treatment recommendations when using DCISionRT News provided by Share this article Share this article LAGUNA HILLS, Calif., April 21, 2021 /PRNewswire/ -- Prelude Corporation (PreludeDx™), a leader in molecular diagnostics and precision medicine for early stage breast cancer, announced results for a prospective study in 44 U.S. academic and community cancer centers that evaluated the impact of DCISionRT on clinicians' recommendations to administer or omit adjuvant radioth...